{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:31:09Z","timestamp":1793043069801,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.autrev.2017.07.005","type":"journal-article","created":{"date-parts":[[2017,7,8]],"date-time":"2017-07-08T18:00:37Z","timestamp":1499536837000},"page":"937-945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"title":["Biomarkers of disease activity in vitiligo: A systematic review"],"prefix":"10.1016","volume":"16","author":[{"given":"R.","family":"Speeckaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Speeckaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"De Schepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"van Geel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2017.07.005_bb0005","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.autrev.2014.12.003","article-title":"Why treatments do(n't) work in vitiligo: an autoinflammatory perspective","volume":"14","author":"Speeckaert","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.005_bb0010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.autrev.2015.12.006","article-title":"Vitiligo: pathogenesis, clinical variants and treatment approaches","volume":"15","author":"Iannella","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.005_bb0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.det.2016.11.004","article-title":"Presentations, signs of activity, and differential diagnosis of vitiligo","volume":"35","author":"Goh","year":"2017","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.autrev.2017.07.005_bb0020","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/DAD.0000000000000539","article-title":"Clinicopathologic analysis of stable and unstable vitiligo: a study of 66 cases","volume":"38","author":"Yadav","year":"2016","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1346-8138.1992.tb03211.x","article-title":"Epidermal changes in active vitiligo","volume":"19","author":"Hann","year":"1992","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/bjd.12034","article-title":"Clinical features and histological findings are potential indicators of activity in lesions of common vitiligo","volume":"168","author":"Benzekri","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0035","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/ijd.1993.32.4.269","article-title":"Ultrastructural study of Vitiligo","volume":"32","author":"Galadari","year":"1993","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0040","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/bjd.13160","article-title":"Possible patterns of epidermal melanocyte disappearance in nonsegmental vitiligo: a clinicopathological study","volume":"172","author":"Benzekri","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0045","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00403-015-1544-4","article-title":"A comparative study of mitochondrial ultrastructure in melanocytes from perilesional vitiligo skin and perilesional halo nevi skin","volume":"307","author":"Ding","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.autrev.2017.07.005_bb0050","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/ijd.12160","article-title":"Assessment of tissue FoxP3+, CD4+ and CD8+ T-cells in active and stable nonsegmental vitiligo","volume":"53","author":"Abdallah","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037513","article-title":"Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo","volume":"7","author":"Lili","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2017.07.005_bb0060","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.1711700209","article-title":"An immunohistological study of cutaneous lymphocytes in vitiligo","volume":"170","author":"Badri","year":"1993","journal-title":"J Pathol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0065","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2016.12.021","article-title":"Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity","volume":"76","author":"Strassner","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0070","doi-asserted-by":"crossref","DOI":"10.1111\/ijd.13564","article-title":"Regulatory T-cell cytokines in patients with nonsegmental vitiligo","author":"Kidir","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0075","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/pcmr.12219","article-title":"Type I interferon signature in the initiation of the immune response in vitiligo","volume":"27","author":"Bertolotti","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.autrev.2017.07.005_bb0080","article-title":"Study of the comparative expression of CXCL9, CXCL10 and IFN\u03b3 in vitiligo and alopecia areata patients","author":"Maouia","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.autrev.2017.07.005_bb0085","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1684\/ejd.2013.2023","article-title":"Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: a case-controlled study on eighty-four patients","volume":"23","author":"Elela","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0090","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cyto.2016.12.014","article-title":"Increased systemic and epidermal levels of IL-17A and IL-1\u03b2 promotes progression of non-segmental vitiligo","volume":"91","author":"Bhardwaj","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.autrev.2017.07.005_bb0095","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2230.2010.03972.x","article-title":"Role of interleukin-17 in the pathogenesis of vitiligo","volume":"36","author":"Bassiouny","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/15569527.2011.560913","article-title":"Tumor necrosis factor-\u03b1 in vitiligo: direct correlation between tissue levels and clinical parameters","volume":"30","author":"Kim","year":"2011","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0105","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1590\/S0100-879X2012007500152","article-title":"Relationship of macrophage migration inhibitory factor levels in PBMCs, lesional skin and serum with disease severity and activity in vitiligo vulgaris","volume":"46","author":"Ma","year":"2013","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.autrev.2017.07.005_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2016.12.028","article-title":"Misbalanced CXCL12 and CCL5 chemotactic signals in vitiligo onset and progression","author":"Rezk","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0923-1811(99)00029-8","article-title":"Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo","volume":"21","author":"Caixia","year":"1999","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.autrev.2017.07.005_bb0120","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjd.12691","article-title":"Inflammasome activation and vitiligo\/nonsegmental vitiligo progression","volume":"170","author":"Marie","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0125","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4103\/0019-5154.185704","article-title":"Heat shock protein-70 expression in vitiligo and its relation to the disease activity","volume":"61","author":"Doss","year":"2016","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0130","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.anndiagpath.2012.11.005","article-title":"Immunohistochemical expression of heat shock protein 70 in vitiligo","volume":"17","author":"Abdou","year":"2013","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0135","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/PAI.0b013e318246c793","article-title":"Immunolocalization of tenascin-C in vitiligo","volume":"20","author":"Abdou","year":"2012","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0140","article-title":"Immunohistochemical expression of Aquaporin-3 protein in vitiligo; a new potential guide for disease activity","author":"Hodeib","year":"2016","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0145","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000338023","article-title":"Expression profile of genes associated with the dopamine pathway in vitiligo skin biopsies and blood sera","volume":"224","author":"Reimann","year":"2012","journal-title":"Dermatology (Basel)"},{"key":"10.1016\/j.autrev.2017.07.005_bb0150","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0190-9622(90)70029-H","article-title":"T cell subpopulations in vitiligo: a chronobiologic study","volume":"22","author":"Mozzanica","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0155","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/pcmr.12105","article-title":"Decreased regulatory T-cells and CD4(+)\/CD8(+) ratio correlate with disease onset and progression in patients with generalized vitiligo","volume":"26","author":"Dwivedi","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.autrev.2017.07.005_bb0160","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1346-8138.2004.tb00514.x","article-title":"T cell subpopulations and IL-2R in vitiligo","volume":"31","author":"Gunduz","year":"2004","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0165","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10354-009-0699-z","article-title":"Lymphocyte imbalance in vitiligo patients indicated by elevated CD4+\/CD8+ T-cell ratio","volume":"159","author":"Pichler","year":"2009","journal-title":"Wien Med Wochenschr"},{"key":"10.1016\/j.autrev.2017.07.005_bb0170","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1046\/j.1523-1747.2001.01363.x","article-title":"HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA\/MART1","volume":"116","author":"Lang","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0175","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1046\/j.1523-1747.2003.12413.x","article-title":"Cytotoxic T lymphocyte reactivity to gp100, MelanA\/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients","volume":"121","author":"Mandelcorn-Monson","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0180","doi-asserted-by":"crossref","first-page":"145409","DOI":"10.1155\/2015\/145409","article-title":"Decreased circulating T regulatory cells in Egyptian patients with nonsegmental vitiligo: correlation with disease activity","volume":"2015","author":"Hegab","year":"2015","journal-title":"Dermatol Res Pract"},{"key":"10.1016\/j.autrev.2017.07.005_bb0185","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/phpp.12104","article-title":"Effect of narrow band-ultraviolet B on CD4(+) CD25(high) FoxP3(+) T-lymphocytes in the peripheral blood of vitiligo patients","volume":"30","author":"Moftah","year":"2014","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.autrev.2017.07.005_bb0190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cca.2013.05.005","article-title":"T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo","volume":"424","author":"Tembhre","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2017.07.005_bb0195","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1684\/ejd.2014.2436","article-title":"Regulatory T cells from active non-segmental vitiligo exhibit lower suppressive ability on CD8+CLA+ T cells","volume":"24","author":"Lin","year":"2014","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0200","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1346-8138.1997.tb02292.x","article-title":"Relationship between levels of soluble interleukin-2 receptors and the types and activity of vitiligo","volume":"24","author":"Honda","year":"1997","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0205","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0923-1811(98)00070-X","article-title":"Serum concentration of the soluble interleukin-2 receptor in vitiligo patients","volume":"19","author":"Yeo","year":"1999","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.autrev.2017.07.005_bb0210","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1001\/jamadermatol.2016.2366","article-title":"Clinical significance of serum soluble CD molecules to assess disease activity in vitiligo","volume":"152","author":"Speeckaert","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0215","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2017.07.005_bb0220","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/bjd.14416","article-title":"Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo","volume":"174","author":"Wang","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0225","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/pcmr.12559","article-title":"Differential expression of CXCL9, CXCL10, and IFN-\u03b3 in vitiligo and alopecia areata patients","volume":"30","author":"Maouia","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.autrev.2017.07.005_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2017.02.012","article-title":"Alterations of CXCL12 in serum of vitiligo patients","author":"Speeckaert","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0235","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.autrev.2016.01.004","article-title":"The role of IL-17 in vitiligo: a review","volume":"15","author":"Singh","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.005_bb0240","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaad.2008.09.048","article-title":"The role of helper and regulatory T cells in the pathogenesis of vitiligo","volume":"60","author":"Basak","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0245","first-page":"423490","article-title":"Association of IFN-\u03b3: IL-10 cytokine ratio with nonsegmental vitiligo pathogenesis","volume":"2015","author":"Ala","year":"2015","journal-title":"Autoimmune Dis"},{"key":"10.1016\/j.autrev.2017.07.005_bb0250","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1089\/jir.2012.0171","article-title":"Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in onset and progression of generalized vitiligo","volume":"33","author":"Dwivedi","year":"2013","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.autrev.2017.07.005_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107020","article-title":"Association of neuropeptide Y (NPY), interleukin-1B (IL1B) genetic variants and correlation of IL1B transcript levels with vitiligo susceptibility","volume":"9","author":"Laddha","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2017.07.005_bb0260","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0923-1811(02)00151-2","article-title":"Increased interleukin-6 and granulocyte-macrophage colony stimulating factor levels in the sera of patients with non-segmental vitiligo","volume":"31","author":"Tu","year":"2003","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.autrev.2017.07.005_bb0265","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/1523-1747.ep12476636","article-title":"Cytolytic antibodies to melanocytes in vitiligo","volume":"100","author":"Cui","year":"1993","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0270","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/1523-1747.ep12492607","article-title":"Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo","volume":"97","author":"Harning","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0275","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/1523-1747.ep12476728","article-title":"Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo","volume":"100","author":"Yu","year":"1993","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0280","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1468-3083.2012.04501.x","article-title":"Melanocyte antigen-specific antibodies cannot be used as markers for recent disease activity in patients with vitiligo","volume":"27","author":"Kroon","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0285","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0625.2010.01181.x","article-title":"Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo","volume":"20","author":"Kemp","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0290","first-page":"17","article-title":"Serum antibodies to melanocytes in patients with vitiligo are predictors of disease progression","volume":"14","author":"Jimenez-Brito","year":"2016","journal-title":"Skinmed"},{"key":"10.1016\/j.autrev.2017.07.005_bb0295","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/bjd.13286","article-title":"High prevalence of circulating autoantibodies against thyroid hormones in vitiligo and correlation with clinical and historical parameters of patients","volume":"171","author":"Colucci","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0300","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4103\/0019-5154.177764","article-title":"Serum homocysteine and total antioxidant status in vitiligo: a case control study in Indian population","volume":"61","author":"Gupta","year":"2016","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0305","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4103\/0019-5154.143506","article-title":"Can systemically generated reactive oxygen species help to monitor disease activity in generalized vitiligo? A pilot study","volume":"59","author":"Pradhan","year":"2014","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0310","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00403-006-0680-2","article-title":"A comparative study of oxidant-antioxidant status in stable and active vitiligo patients","volume":"298","author":"Ines","year":"2006","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.autrev.2017.07.005_bb0315","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1046\/j.0022-202x.2001.01459.x","article-title":"Mitochondrial impairment in peripheral blood mononuclear cells during the active phase of vitiligo","volume":"117","author":"Dell'Anna","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0320","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12291-010-0045-7","article-title":"Study of oxidative stress in vitiligo","volume":"26","author":"Jain","year":"2011","journal-title":"Indian J Clin Biochem"},{"key":"10.1016\/j.autrev.2017.07.005_bb0325","first-page":"720","article-title":"Is there a relationship between homocysteine and vitiligo? A pilot study","volume":"159","author":"Shaker","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0330","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/jcla.20442","article-title":"increased level of serum homocysteine in vitiligo","volume":"25","author":"Singh","year":"2011","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.autrev.2017.07.005_bb0335","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1155\/2012\/540597","article-title":"Serum homocysteine, vitamin B12, folic acid levels and methylenetetrahydrofolate reductase (MTHFR) gene polymorphism in vitiligo","volume":"33","author":"Yasar","year":"2012","journal-title":"Dis Markers"},{"key":"10.1016\/j.autrev.2017.07.005_bb0340","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/bjd.12467","article-title":"Association of NLRP1 genetic variants and mRNA overexpression with generalized vitiligo and disease activity in a Gujarat population","volume":"169","author":"Dwivedi","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2017.01.033","article-title":"S100B is a potential disease activity marker in non-segmental vitiligo","author":"Speeckaert","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0350","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jdermsci.2013.04.026","article-title":"Correlation of increased MYG1 expression and its promoter polymorphism with disease progression and higher susceptibility in vitiligo patients","volume":"71","author":"Dwivedi","year":"2013","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.autrev.2017.07.005_bb0355","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1034\/j.1600-0749.2000.130106.x","article-title":"Higher plasma catecholamine and metabolite levels in the early phase of nonsegmental vitiligo","volume":"13","author":"Cucchi","year":"2000","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.autrev.2017.07.005_bb0360","first-page":"43","article-title":"Assessment of serum levels of granulocyte-macrophage colony-stimulating factor (GM-CSF) among non-segmental vitiligo patients: a pilot study","volume":"24","author":"Abdellatif","year":"2015","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"10.1016\/j.autrev.2017.07.005_bb0365","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0923-1811(01)00134-7","article-title":"Levels of neuropeptide-Y in the plasma and skin tissue fluids of patients with vitiligo","volume":"27","author":"Tu","year":"2001","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.autrev.2017.07.005_bb0370","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3349\/ymj.1994.35.4.404","article-title":"Immunohistochemical studies from vitiligo-comparison between active and inactive lesions","volume":"35","author":"Ahn","year":"1994","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.autrev.2017.07.005_bb0375","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1365-2133.2008.08785.x","article-title":"Gene expression study of IL10 family genes in vitiligo skin biopsies, peripheral blood mononuclear cells and sera","volume":"159","author":"R\u00e4tsep","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2017.07.005_bb0385","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jaad.2016.12.040","article-title":"Clinical markers of vitiligo activity","volume":"76","author":"Benzekri","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2017.07.005_bb0395","first-page":"S446","article-title":"Stem cell factor immunohistochemical expression in vitiligo vulgaris","volume":"455","author":"Abd El All","year":"2009","journal-title":"Virchows Arch"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217301738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217301738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T21:16:11Z","timestamp":1602450971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997217301738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":77,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1568997217301738"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2017.07.005","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers of disease activity in vitiligo: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2017.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}